Pfizer-Gene Therapy Site-Preparedness


Convocatoria "cerrada"
Me interesa
Entidad convocante:
International Pharmaceutical Federation (FIP) and Pfizer
Categoría:
Projectes de recerca
Ámbito:
Internacional
Inicio:
Plazo interno:
Plazo real:
Cuantía:
Individual projects requesting up to $50,000 will be considered. The estimated total available budget related to this RFP is $150,000.
Descripción:

This Request for Proposals (RFP) is for initiatives that span multiple rare disease areas. The International Pharmaceutical Federation (FIP) and Pfizer Global Medical Grants are collaborating to offer a new competitive grant opportunity focused on Pharmacy teams and the integration of gene therapy into the treatment armamentarium for patients with a Rare Disease. The focus is the roles of pharmacy in ensuring gene therapy site preparedness in the management of rare diseases, and then by sharing learnings and experiences more widely. 

Requisitos

Applicant must be a FIP Member Organization or collaborate with a FIP Member Organization or constituency.

Only organizations are eligible to receive grants, not individuals or medical practice groups.

Projects that will be considered for support will focus on operationally preparing and/or optimizing Institutional Pharmacists for the integration of recombinant Adeno-Associated Virus (rAAV) gene therapy into the treatment armamentarium for patients with a Rare Disease.

Support is available for the development of initiatives that will result in operational preparedness, needs-assessment, development of leadership, standards of care, best practices, SOP development, site readiness, support and/or operational training of pharmacists to improve the site's readiness for rAAV gene therapy delivery.

Proposals should be related to rAAV gene therapy operational quality improvement that is therapeutic area and disease area agnostic (i.e., not related to a specific rare disease or group of rare diseases)

Proposals tailored to a specific rare disease or group of rare diseases will not be considered.

Proposals that are primarily related to gene therapy medical and scientific education will not be considered.

Splicitud

In case of interest please click on "m'interessa" and we will contact you.